Ms. Jinhua Zhang, Founder, Chairwoman, and CEO of IASO Bio, stated: ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Panelists discuss how to manage an aggressive case of early posttransplant progression in a young woman with functionally high-risk multiple myeloma (MM), focusing on rapid intervention strategies and ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood ...

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

People are living longer, living better with multiple myeloma. But I think for the vast majority of people who are diagnosed, we still don't have a curative treatment for multiple myeloma, so that, to ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Columbus’ John B Amos Cancer Center is now leading the way to administer a new cancer treatment in the Peach State.The ...

Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients ...

Antengene’s Xpovio approved for reimbursement in Taiwan to treat adult patients with relapsed/refractory multiple myeloma: Shanghai Friday, February 14, 2025, 16:00 Hrs [IST] An ...